Sarcopenia in CKD: A roadmap from basic pathogenetic mechanisms to clinical trials
Entity
UAM. Departamento de Medicina; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)Publisher
Oxford University PressDate
2019Citation
10.1093/ckj/sfz001
Clinical Kidney Journal 12.1 (2019): 110-112
ISSN
2048-8505 (print); 2048-8513 (online)DOI
10.1093/ckj/sfz001Editor's Version
https://doi.org/10.1093/ckj/sfz001Subjects
Chronic kidney disease; Exercise; Frailty; Inflammation; Rotein-energy wasting; Sarcopenia; Satellite cell; TWEAK; Osteosarcopenia; MedicinaAbstract
Sarcopenia and frailty are recognized as key risk factors for adverse outcomes in patients on renal replacement therapy or
with non-dialysis chronic kidney disease (CKD). However, there is still debate about their pathogenesis and, thus, about the
best therapeutic approaches, as well as the impact on outcomes of current approaches based on different exercise
programmes. In the past two issues of Clinical Kidney Journal, several manuscripts address the issue of sarcopenia in CKD
from the point of view of pathogenesis and new therapeutic approaches, monitoring of results, implementation of exercise
programmes and specific potential benefits of exercise programmes in dialysis and non-dialysis CKD patients, as assessed by clinical trials
Files in this item
Google Scholar:Ortiz Arduán, Alberto
-
Sánchez Niño, María Dolores
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.